动脉粥样硬化性心血管疾病人群降脂治疗强化的模拟研究
结果显示,强化前仅25.2%患者LDL-C<70 mg/dL,强化后99.3%可达标,其中仅14%需加用PCSK9抑制剂。
要点
- ASCVD患者降脂治疗与指南推荐存在巨大差距,强化前仅25.2% LDL-C达标。
- 阶梯式口服降脂强化可使99.3%患者LDL-C<70 mg/dL。
- 仅14%患者需加用PCSK9抑制剂即可达标。
核心结论
- 在假设无降脂治疗不耐受且完全依从的模型中,口服降脂治疗强化可使大多数ASCVD患者LDL-C<70 mg/dL,仅少数需PCSK9抑制剂。
主要发现
- 模拟队列中,强化前51.5%使用他汀单药治疗,1.7%使用他汀联合依折麦布,仅25.2% LDL-C<70 mg/dL。
- 强化后99.3%可达LDL-C<70 mg/dL,其中67.3%经他汀单药、18.7%经他汀联合依折麦布、14%需加用PCSK9抑制剂。
关键数值与推荐
- 对LDL-C≥70 mg/dL者,未用他汀者给予阿托伐他汀20 mg,强化步骤依次为:上调至阿托伐他汀80 mg、加用依折麦布、加用阿利rocumab 75 mg、上调至阿利rocumab 150 mg。
- 敏感性分析中PCSK9抑制剂包括evolocumab。
临床怎么用
- 临床应首先强化口服降脂治疗(他汀上调、加用依折麦布),仅少数患者需PCSK9抑制剂即可使绝大多数ASCVD患者LDL-C达标。
局限性
- 模型假设无降脂治疗不耐受且完全依从,可能高估强化效果。
- 疗效数据来源于已发表研究,可能存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with atherosclerotic cardiovascular disease (ASCVD), guidelines recommend optimizing statin treatment, and consensus pathways suggest use of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despite use of statins. Recent trials have provided evidence of benefit in reduction of cardiovascular events with these agents. OBJECTIVE: To estimate the percentage of patients with ASCVD who would require a PCSK9 inhibitor when oral lipid-lowering therapy (LLT) is intensified first. DESIGN, SETTING, AND PARTICIPANTS: This simulation model study used a large administrative database of US medical and pharmacy claims to identify a cohort of 105 269 patients with ASCVD enrolled from January 1, 2012, through December 31, 2013, who met the inclusion criteria (database cohort). Patients were sampled with replacement (bootstrapping) to match the US epidemiologic distribution and entered into a Monte Carlo simulation (simulation cohort) that applied stepwise treatment intensification algorithms in those with LDL-C levels of at least 70 mg/dL. All patients not initially receiving a statin were given atorvastatin, 20 mg, and the following LLT intensification steps were applied: uptitration to atorvastatin, 80 mg; add-on ezetimibe therapy; add-on alirocumab therapy, 75 mg (a PCSK9 inhibitor); and uptitration to alirocumab, 150 mg. Sensitivity analyses included evolocumab as a PCSK9 inhibitor. Efficacy was estimated from published studies and incorporated patient-level variation. Data were analyzed from December 2015 to May 2017. EXPOSURES: Treatment intensification strategies with LLT. MAIN OUTCOMES AND MEASURES: Use of LLT among the population with ASCVD and distributions of LDL-C levels under various treatment intensification scenarios. RESULTS: Inclusion criteria were met by 105 269 individuals in the database cohort (57.2% male and 42.8% female; mean [SD] age, 65.1 [12.1] years). In the simulation cohort (1 million patients; 54.8% male and 45.2% female; mean [SD] age, 66.4 [12.2] years), before treatment intensification, 51.5% used statin monotherapy and 1.7% used statins plus ezetimibe. Only 25.2% achieved an LDL-C level of less than 70 mg/dL. After treatment intensification, 99.3% could achieve an LDL-C level of less than 70 mg/dL, including 67.3% with statin monotherapy, 18.7% with statins plus ezetimibe, and 14% with add-on PCSK9 inhibitor. CONCLUSIONS AND RELEVANCE: Large gaps exist between recommendations and current practice regarding LLT in the population with ASCVD. In our model that assumes no LLT intolerance and full adherence, intensification of oral LLT could achieve an LDL-C level of less than 70 mg/dL in most patients, with only a modest percentage requiring a PCSK9 inhibitor.
引用
- Cannon CP, Khan I, Klimchak AC, et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017. PMID: 28768335. doi:10.1001/jamacardio.2017.2289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。